Feasibility of haloperidol-anchored albumin nanoparticles loaded with doxorubicin as dry powder inhaler for pulmonary delivery

References

• Mylonakis N, Athanasiou A, Ziras N, et al. Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer 2010;68:240–247
   PubMed Web of Science ®Google Scholar
• Sharma S, White D, Imondi AR, et al. Development of inhalational agents for oncologic use. J Clin Oncol 2001;19:1839–1847
   PubMed Web of Science ®Google Scholar
• Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583–592
   PubMed Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588–599
   PubMed Web of Science ®Google Scholar
• Tatsumura T, Koyama S, Tsujimoto M, et al. Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical. Br J Cancer 1993;68:1146–1149
   PubMed Web of Science ®Google Scholar
• Moody TW, Leyton J, John C. Sigma ligands inhibit the growth of small cell lung cancer cells. Life Sci 2000;66:1979–1986
   PubMed Web of Science ®Google Scholar
• Banerjee R, Tyagi P, Li S, Huang L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 2004;112:693–700
   PubMed Web of Science ®Google Scholar
• Buxton D. The promise of nanotechnology for heart, lung and blood diseases. Expert Opin Drug Deliv 2006;3:173–175
   PubMedGoogle Scholar
• Pilcer G, Vanderbist F, Amighi K. Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery. Int J Pharm 2009;365:162–169
   PubMed Web of Science ®Google Scholar
• Rahimnejad M, Jahanshahi M, Najafpour GD. Production of biological nanoparticles from bovine serum albumin for drug delivery. Afr J Biotechnol 2006;5:1918–1923
   Web of Science ®Google Scholar
• Langer K, Balthasar S, Vogel V, et al. Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 2003;257:169–180
   PubMed Web of Science ®Google Scholar
• Sebak S, Mirzaei M, Malhotra M, et al. Human serum albumin nanoparticles as an efficient noscapine drug delivery system for potential use in breast cancer: preparation and in vitro analysis. Int J Nanomed 2010;5:525–532
   PubMed Web of Science ®Google Scholar
• Wang G, Siggers K, Zhang S, et al. Preparation of BMP-2 containing bovine serum albumin (BSA) nanoparticles stabilized by polymer coating. Pharm Res 2008;25:2896–2909
   PubMed Web of Science ®Google Scholar
• Adami RC, Rice KG. Metabolic stability of glutaraldehyde cross-linked peptide DNA condensates. J Pharm Sci 1999;88:739–746
   PubMed Web of Science ®Google Scholar
• Maghsoudi A, Shojaosadati SA, Farahani EV. 5-Fluorouracil-loaded BSA nanoparticles: formulation optimization and in vitro release study. AAPS PharmSciTech 2008;9:1092–1096
   PubMed Web of Science ®Google Scholar
• Arnedo A, Espuelas S, Irache JM. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int J Pharm 2002;244:59–72
   PubMed Web of Science ®Google Scholar
• Yang L, Cui F, Cun D, et al. Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. Int J Pharm 2007;340:163–172
   PubMed Web of Science ®Google Scholar
• Müller RH, Maassen S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996;4:161–170
   PubMed Web of Science ®Google Scholar
• Rubino OP, Kowalsky R, Swarbrick J. Albumin microspheres as a drug delivery system: relation among turbidity ratio, degree of cross-linking, and drug release. Pharm Res 1993;10:1059–1065
   PubMed Web of Science ®Google Scholar
• Li FQ, Su H, Wang J, et al. Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting. Int J Pharm 2008;349:274–282
   PubMed Web of Science ®Google Scholar
• Tomoda K, Ohkoshi T, Nakajima T, Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Colloids Surf B Biointerf 2008;64:70–76
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang Y, Tang X. Characterization of a new inhalable thymopentin formulation. Int J Pharm 2009;375:1–7
   PubMed Web of Science ®Google Scholar
• Maas SG, Schaldach G, Littringer EM, et al. The impact of spray drying outlet temperature on the particlemorphology of mannitol. Powder Technol 2011;213:27–35
   Web of Science ®Google Scholar
• Jones MD, Harris H, Hooton JC, et al. An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive–adhesive force balances. Eur J Pharm Biopharm 2008;69:496–507
   PubMed Web of Science ®Google Scholar
• Raula J, Lähde A, Kauppinen EI. Aerosolization behavior of carrier-free l-leucine coated salbutamol sulphate powders. Int J Pharm 2009;365:18–25
   PubMedGoogle Scholar
• Littringer EM, Mescher A, Schroettner H, et al. Spray dried mannitol carrier particles with tailored surface properties – the influence of carrier surface roughness and shape. Eur J Pharm Biopharm 2012;82:194–204
   PubMed Web of Science ®Google Scholar
• Schüle S, Schulz-Fademrecht T, Garidel P, et al. Stabilization of IgG1 in spray-dried powders for inhalation. Eur J Pharm Biopharm 2008;69:793–807
   PubMed Web of Science ®Google Scholar
• Kumon M, Lip Kwok PC, Adi H, et al. Can low-dose combination products for inhalation be formulated in single crystalline particles? Eur J Pharm Sci 2010;40:16–24
   PubMed Web of Science ®Google Scholar